Sjögren Europe’s General Meeting (SEGM) brought together a vibrant community of experts, patient advocates, and industry leaders in Lisbon to address one of the most pressing challenges for Sjögren’s patients: advancing clinical trials. With participants from over 15 countries, this year’s theme, “Unlocking Clinical Trials: From Design to Participation and Beyond,” focused on shaping the future of medical research to enhance the quality of life for those living with this complex autoimmune disease.
Sjögren’s disease is far more than the dry eyes and mouth commonly associated with it. As a systemic condition, it can impact multiple organs, causing profound challenges for patients. Diagnosis remains a global struggle, often delayed by inadequate knowledge and the difficulty of interpreting diverse symptoms. The meeting highlighted the urgency of tackling these barriers, improving disease literacy, and accelerating the development of innovative treatments.
Central to the discussions was the necessity of collaboration among clinicians, researchers, patients, and the pharmaceutical industry. This multi-stakeholder approach is essential to developing treatments that address both the physical and emotional burdens of the disease. Representatives emphasized the importance of clinical trials as the cornerstone of progress, fostering hope for breakthroughs in treatment.
The meeting’s success was underpinned by the support of esteemed sponsors, including Johnson & Johnson Innovative Medicine, Novartis, AMGEN, Bristol Myers Squibb, and EyeD Pharma. These organizations underscored their commitment to addressing unmet medical needs and driving innovation in the field.
Sjögren Europe, established in 2019, continues to play a pivotal role in patient advocacy, awareness, and research collaboration. By uniting national associations and amplifying patient voices, it strives to create a future where Sjögren’s patients receive earlier diagnoses, equitable access to care, and effective treatments.
Quotes from the Event:
- “There is no treatment for Sjögren’s without clinical trials. Improving diagnosis, developing powerful treatments, and ensuring accessibility are the keys to reducing the burden of this disease.”
- “Every patient deserves hope, starting at the moment of diagnosis.”
For more information, visit Sjögren Europe.
